Jes Ostergaard, CEO of DakoCytomation, said, "This is an important agreement for DakoCytomation as we work to expand our business in the pharmacoDiagnostic arena.  We are excited to partner with one of the leading biotechnology companies in the world in developing yet another tool to help physicians identify patients for treatment with new targeted therapies."

David C. Stump, M.D., Executive Vice President, Drug Development, Human Genome Sciences, said, "DakoCytomation is the leader in developing clinical tests to help assess candidates for specific targeted therapies.  The immunohistochemical tests under development as a result of the collaboration between our companies will play an important role in clinical trials in exploring the correlation between TRAIL Receptor-1 and TRAIL Receptor-2 expression and clinical response to treatment of various cancers with TRAIL-R1 and TRAIL-R2 agonistic human monoclonal antibodies."

Health professionals interested in more information about trials involving HGSI products are encouraged to inquire via the Contact Us section of the Human Genome Sciences web site, www.hgsi/products/request.html, or by calling (301) 610-5790, extension 3550.

Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based protein and antibody drugs to patients.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.